The future of peptide-based drugs

Area of Science:

• Drug discovery and development
• Medicinal chemistry
• Pharmacology

Background:

• Current drugs fall into two main classes: small molecules (<500 Da) with oral bioavailability but potential selectivity issues, and biologics (>5000 Da) with high specificity but poor bioavailability requiring injection.
• Small molecule drugs can cause side effects due to limited target selectivity, while biologics, despite high specificity, face challenges like poor membrane permeability and metabolic instability.

Purpose of the Study:

• To explore the potential of peptide drugs as an intermediate class of therapeutics.
• To combine the advantages of small molecules (e.g., oral bioavailability, stability) with those of biologics (e.g., target specificity, potency).

Main Methods:

• Review of existing literature and examples of peptide drugs.
• Analysis of the physicochemical properties and therapeutic potential of peptides.
• Discussion of opportunities and challenges in peptide drug development.

Main Results:

• Peptides represent a viable molecular weight range (between small molecules and biologics) for drug development.
• Selected peptide examples demonstrate their potential for high target specificity and potency.
• Peptides offer a pathway to overcome limitations of current drug classes, such as improving oral bioavailability and reducing side effects.

Conclusions:

• Peptide drugs are crucial for developing next-generation therapeutics by bridging the gap between small molecules and biologics.
• Further research and development in peptide therapeutics are essential to overcome existing challenges and unlock their full potential.
• Exploiting peptide drugs offers new opportunities for improved drug efficacy and patient compliance.